Open Access<p>Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection</p>
Author(s) -
Yuzhu Dong,
Ying Li,
Ying Zhang,
Dan Sun,
Qian Du,
Tao Zhang,
Mengmeng Teng,
Ruiying Han,
Yan Wang,
Li Zhu,
Jin’e Lei,
Yalin Dong,
Taotao Wang
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s241648
Subject(s) - cefoperazone , propensity score matching , medicine , sulbactam , cohort , retrospective cohort study , beta lactamase inhibitors , cirrhosis , antibiotics , gastroenterology , antibiotic resistance , microbiology and biotechnology , imipenem , biology
Gram-negative bacteria bloodstream infection (GNB-BSI) results in considerable mortality and hospitality costs in cirrhotic patients. β-lactam/β-lactamase inhibitor combinations (BLBLIs) and carbapenems (CARs) are widely recommended for treating GNB-BSI in cirrhotic patients, while the efficacy and cost-effectiveness of two strategies have never been evaluated. Therefore, we conducted a retrospective cohort study to evaluate the efficacy and the cost-effectiveness of BLBLIs and CARs.